Evidence map›Paper›PMID 41571939›Full record

ArticleNPJ precision oncology2026

Translating spatial transcriptomic signatures in adenosquamous carcinoma into bulk prognostic biomarkers in lung adenocarcinoma: a bottom-up approach.

Keiichi Hatakeyama, Takuya Kawata, Koji Muramatsu, Takuma Oishi, Takeshi Nagashima, Ai Sakai, Terumi Nishimura, Keiichi Ohshima, Sumiko Ohnami, Shumpei Ohnami and 8 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Keiichi Hatakeyama *Cancer Multiomics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan. k.hatakeyama@scchr.jp.
Takuya Kawata *Division of Pathology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.
Koji MuramatsuDivision of Pathology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.
Takuma OishiDivision of Pathology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.
Takeshi NagashimaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Ai SakaiSRL Inc., Shinjuku-ku, Tokyo, Japan.
Terumi NishimuraCancer Multiomics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Keiichi OhshimaMedical Genetics Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Sumiko OhnamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Shumpei OhnamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yuji ShimodaCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Akane NaruokaDrug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Koji MaruyamaExperimental Animal Facility, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Kenichi UrakamiCancer Diagnostics Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.
Yasuhisa OhdeDivision of Thoracic Surgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Takashi SuginoDivision of Pathology, Shizuoka Cancer Center Hospital, Sunto-gun, Shizuoka, Japan.
Ken YamaguchiShizuoka Cancer Center, Shizuoka, Japan.

Funding

Japan Agency for Medical Research and Development JP22k0106689Japan Society for the Promotion of Science JP22K07315
6 · The paper itself

Abstract

Spatial transcriptomics enables the detection of rare or transitional tumor states not captured by bulk transcriptomics or immunohistochemistry (IHC). However, translating these spatially defined states into clinically relevant biomarkers is challenging, because signals from minor populations are underrepresented or masked in bulk data. Lung adenosquamous carcinoma (ASC), containing intermixed adenocarcinoma and squamous components, provides a model to study lineage transitions and poorly differentiated states unresolved in bulk datasets. Spatial transcriptomic profiling of ASC was integrated with TTF-1 and p40 IHC to detect tumor populations lacking these markers. Gene signatures from IHC-negative populations were projected onto bulk lung adenocarcinoma datasets to assess prognostic relevance. We implemented a color-space uniform manifold approximation and projection visualization (RGB-UMAP) to enhance the spatial mapping of rare transcriptional states that were unresolved by conventional clustering. We identified a TTF-1/p40-negative tumor cell population with a hybrid adenocarcinoma-squamous expression pattern and upregulation of SLC2A1 (GLUT1). RGB-UMAP clarified these states and distinguished them from normal epithelial cells. In bulk lung adenocarcinoma cohorts, high SLC2A1 expression stratified patients with poorer survival. This study demonstrates a bottom-up biomarker discovery strategy translating spatially defined, IHC-negative tumor cell populations in ASC into stratifiers for lung adenocarcinoma.

Identifiers

PMID41571939
PMCPMC12929729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.